---
title: "Aidea Pharma's net loss for the year 2024 is 130 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/229936421.md"
description: "According to the Zhitong Finance APP, Aidea Pharma disclosed its performance preliminary report for the year 2024. During the reporting period, the company's total operating revenue was 419 million yuan, an increase of 1.92% compared to the same period last year; the net loss attributable to the owners of the parent company was 130 million yuan, a decrease of 70.79% compared to the same period last year"
datetime: "2025-02-27T14:49:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/229936421.md)
  - [en](https://longbridge.com/en/news/229936421.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/229936421.md)
generator: "portal-rs"
---

# Aidea Pharma's net loss for the year 2024 is 130 million yuan

According to the Zhitong Finance APP, Aidea Pharma (688488.SH) disclosed its performance preliminary report for the year 2024. During the reporting period, the company's total operating revenue was 419 million yuan, an increase of 1.92% compared to the same period last year; the net loss attributable to the owners of the parent company was 130 million yuan, which will decrease by 70.79% compared to the same period last year

### Related Stocks

- [688488.CN](https://longbridge.com/en/quote/688488.CN.md)

## Related News & Research

- [Can Xiaomi Take On Porsche On Its Home Turf? It’s About To Try](https://longbridge.com/en/news/297946941.md)
- [Church's Texas Chicken's China debut drew 2-hour lines — and $22 offers to wait in them](https://longbridge.com/en/news/297600833.md)
- [LithiumBank shares trade on Germany’s Tradegate Exchange under symbol HT9](https://longbridge.com/en/news/297910536.md)
- [Costa Rica President: U.S. forces would help national security](https://longbridge.com/en/news/298065948.md)
- [China Resources Pharma unit KPC wins registration to issue RMB 1 billion in medium-term notes](https://longbridge.com/en/news/297630970.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**